[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Al-Mustansiriyah University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":293},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,51,77,99,119,145,167,191,212,241,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100635016","effect-of-non-surgical-periodontal-therapy-on-salivary-biomarkers-in-smokers-and-non-smokers-with-periodontitis-100635016",false,"NCT07547202","Effect of Non-Surgical Periodontal Therapy on Salivary Biomarkers in Smokers and Non-Smokers With Periodontitis","The Significance of Non-Surgical Periodontal Therapy on Salivary Dkk-1, Sclerostin, and PLAP-1 Levels in Smoker and Non-Smoker Patients With Periodontitis: A Clinical Comparative Study","NSPT-Biomarker","Inclusion Criteria:\n\n* Systemically healthy.\n* Diagnosed with Stage II and III periodontitis.\n* Presence of ≥ 20 teeth (excluding third molars).\n* Current smoker OR non-smoker\n\nExclusion Criteria:\n\n* Presence of systemic diseases affecting the periodontium.\n* Use of medications affecting inflammation.\n* Received periodontal therapy in the past 6 months.\n* Received antibiotic therapy in the last 3 months.\n* Alcohol use.","ALL","18 Years",{"count":20,"type":21},44,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates the effect of non-surgical periodontal therapy on salivary biomarkers (Dkk-1, Sclerostin, and PLAP-1) and clinical periodontal parameters in patients with periodontitis. Periodontitis is a chronic inflammatory disease that destroys tooth-supporting tissues. Smoking is a significant risk factor that worsens periodontal destruction and reduces the effectiveness of standard therapies.\n\n* The trial is a non-randomized comparative clinical study.\n* It includes 44 adult patients diagnosed with Stage II and III periodontitis.\n* The participants are divided into two equal groups: 22 current smokers and 22 non-smokers.\n* Participants will undergo a baseline examination, followed by standardized non-surgical periodontal therapy consisting of scaling and root planing.\n* A follow-up visit will be conducted six weeks post-therapy to repeat clinical measurements and saliva collection.\n* The primary objective is to evaluate changes in salivary biomarker levels and clinical parameters (Plaque Index, Gingival Index, bleeding on probing, Probing Pocket Depth, Clinical Attachment Level) after treatment.",[27,28],"Periodontitis","Smoking ( Cigarette)",[27,30,31,32,33,34,35,36,37],"Smoking","Non-surgical periodontal therapy","Scaling and root planing","Salivary biomarkers","Dkk-1","Sclerostin","PLAP-1","SOST","RECRUITING","2026-04-20",{"date":41,"type":42},"2026-04-23","ACTUAL",{"date":44,"type":42},"2026-01-01",{"date":46,"type":21},"2026-10-01",{"name":48,"class":49},"Al-Mustansiriyah University","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100586903","the-effect-of-monk-fruit-and-splenda-on-salivary-ph-and-streptococcus-mutans-count-in-vivo-study-100586903","NCT06921434","the Effect of Monk Fruit and Splenda on Salivary Ph and Streptococcus Mutans Count in Vivo Study","Comparative Evaluation of Monk Fruit and Splenda on Salivary ph and Streptococcus Mutans Growth (an in Vivo Study)","Inclusion Criteria:\n\nparticipants aged (20-24) years.\n\n* No active carious lesions or oral diseases.\n* Generally healthy individuals without systemic illnesses.\n* No prior use of preventive dental treatments\n\nExclusion Criteria:\n\n* Participants currently undergoing dental treatment.\n* Those taking medications that alter saliva flow.\n* Presence of painful oral conditions or systemic diseases. Participants have active caries",true,"20 Years","24 Years",{"count":62,"type":21},90,[24],"This study aims to evaluate the changes in salivary pH and Streptococcus mutans count by preparing a solution containing these sweeteners dissolved in distilled water and administering it to the participants. Saliva samples will be collected before using the mouth rinse, and salivary pH will be measured using a pH meter, while S. mutans count will be analyzed in the laboratory.\n\nAfter consuming the solution, salivary pH will be assessed at 1 minute, 15 minutes, and 30 minutes, while the growth of S. mutans will be examined 30 minutes post-rinse.",[66],"Caries Active","NOT_YET_RECRUITING","2025-09-23",{"date":70,"type":42},"2025-09-24",{"date":72,"type":21},"2025-10-01",{"date":74,"type":21},"2025-12-01",{"name":48,"class":49},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":76},"100606974","phase-2-effects-of-adding-quercetin-or-alpha-lipoic-acid-to-usual-care-on-symptoms-and-blood-markers-in-iraqi-women-with-polycystic-ovary-syndrome-100606974","NCT07182526","Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome","Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients","Inclusion Criteria:\n\n* • Newly diagnosed patients should be at reproductive aged from 18-40 years.\n\n  * Patients diagnosed with presence of micro polycystic ovaries at ultrasound.\n  * Oligomenorrhea with inter-menstrual intervals longer than 35 days.\n  * Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).\n  * Normal PRL levels.\n\nExclusion Criteria:\n\n* • Presence of enzymatic adrenal deficiency and\u002For other endocrine disease, including diabetes.\n\n  * Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction).\n  * Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs.\n  * Pregnant women.",{"count":85,"type":21},150,[87],"PHASE2","This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.",[90],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","2025-09-18",{"date":93,"type":42},"2025-09-19",{"date":95,"type":21},"2025-09-20",{"date":97,"type":21},"2026-05-01",{"name":48,"class":49},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":76},"100581458","phase-4-aflibercept-and-bevacizumab-for-diabetic-maculopathies-100581458","NCT06850571","Aflibercept and Bevacizumab for Diabetic Maculopathies","Evaluation of the Clinical Outcomes and Cost-effectiveness of Aflibercept and Bevacizumab in Iraqi Patients With Diabetic Maculopathies: Open Label Parallel Groups Clinical Trial","Inclusion Criteria:\n\n* Patients with type 2 diabetes mellites.\n* Patients diagnosed with diabetic maculopathies, including focal and diffuse maculopathies, according to Early Treatment of Diabetic Retinopathy Study (ETDRS) criteria\n* Patients with reduced or reduced vision (6\u002F9-6\u002F90) according to visual acuity and significant foveolar thickening on OCT (more than 250 μm)\n* Patients will be treated with intravitreal anti-VEGF treatment, aflibercept, or bevacizumab for three successive monthly injections.\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes mellites\n* Patients with type 2 on insulin therapy.\n* Patients who were previously treated with intravitreal anti-VEGF within the previous three months or intravitreal corticosteroids for six months\n* Prior macular photocoagulation or photodynamic therapy, prior intraocular surgeries within three months (laser \\& surgery may cause edema)\n* Pregnant or nursing women\n* In patients with a history of thromboembolic events, systemic VEGF inhibition is likely to cause cardiovascular complications, such as arterial thromboembolic events.\n* Patients major surgery within the previous one year or planned within the next few months that may interfere with anti-VEGF treatment\n* Uncontrolled hypertension as hypertension is associated with the use of VEGF antagonists.\n* Known coagulation abnormalities or current use of anticoagulative medication other than aspirin.\n* Hemorrhagic macular infarction is reported with the use of VEGF antagonists.\n* Patients with intraocular pressure more than 25 mmHg\n* Presence of iris neovascularization\u002Fvitreous hemorrhage","40 Years",{"count":108,"type":21},102,[110],"PHASE4","The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include:\n\n* Functional changes: The visual outcomes achieved by testing visual acuity\n* Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).",[113],"Diabetic Maculopathy",{"date":93,"type":42},{"date":116,"type":42},"2025-02-20",{"date":74,"type":21},{"name":48,"class":49},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":76},"100603218","phase-4-exploring-the-efficacy-safety-of-a-modified-starting-dosage-of-avatrombopag-in-immune-throbocytopenia-itp---a-pilot-study-100603218","NCT07133659","Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study","Ava dosing","Inclusion Criteria:\n\n1. Male or female aged ≥18 years.\n2. Diagnosis of primary ITP and having a platelet count of \\\u003C 30 x109\u002FL measured within two weeks prior to inclusion with failure to achieve response or relapse after at least one cycle of dexamethasone (20-40 mg daily for 4 days) or prednisone \u002Fprednisolone (1 mg\u002Fkg for at least two weeks). Shorter courses or lower doses are allowed if discontinued or modified due to side effects.\n3. Clinical need for second (subsequent) line treatment with a platelet elevating therapy assessed by the physician in charge.\n4. Signed and dated written informed consent.\n\nExclusion Criteria:\n\n1. Previous treatment with TPO-RA.\n2. Pregnancy or lactation.\n3. Patients with active serious bleeding or at high risk of bleeding as judged by physician in charge.\n4. Females of child-bearing potential refusing to follow effective contraceptive methods (as described in SmPC) during treatment with Avatrombopag.\n5. Secondary ITP defined as ITP secondary to lymphoma or chronic lymphocytic leukemia; ITP secondary to the following autoimmune disorders Systemic Lupus Erythematosus or Antiphospholipid Syndrome; ITP secondary to Common Variable Immune Deficiency; ITP secondary to the following viral infections eg Human Immunodeficiency Virus.\n6. Concomitant autoimmune hemolytic anemia, Evans syndrome.\n7. Presence of any serious comorbidity where the condition may worsen the study drugs.\n8. Presence of active malignancy unless deemed cured by adequate treatment. Participants with the following neoplastic conditions can be included:\n\n   * Monoclonal gammopathy of undetermined significance (MGUS) or monoclonal B lymphocytosis of undetermined significance (MBUS)\n   * Basal\u002Fsquamous cell carcinoma of the skin\n   * Carcinoma in situ of the cervix\n   * Carcinoma in situ of the breast\n   * Incidental histological finding of prostate cancer (TNM stage T1a or T1b)\n9. Patients with history of poor compliance or history of alcohol\u002Fdrug abuse or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent.\n\n   \\-",{"count":127,"type":21},25,[110],"This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag and explore the efficacy and safety of lower starting dose of avatrombopag",[131],"ITP - Immune Thrombocytopenia",[133,134,135,136],"ITP","thrombocytopenia","Avatrombopag","thrombopoietin receptor agonist","2025-08-14",{"date":139,"type":42},"2025-08-21",{"date":141,"type":42},"2025-06-08",{"date":143,"type":21},"2027-07-08",{"name":48,"class":49},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":58,"sex":152,"minAge":153,"maxAge":106,"enrollmentInfo":154,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100594487","oral-health-condition-among-a-group-of-ionizing-radiation-field-workers-100594487","NCT07020078","Oral Health Condition Among a Group of Ionizing Radiation Field Workers","Salivary Redox Biomarkers in Relation to Oral Health Condition Among a Group of Ionizing Radiation Field Workers","Inclusion Criteria:\n\n* male, 30\\_40 years ,no history of systemic disease, no medical treatment taken at least 3 months before sampling and the subjects are exposed to radiation 5\\_ 10 years\n\nExclusion Criteria:\n\n* subjects with medical history , subjects are taken medications during last 3 months , the subjects are exposed to radiation less than 5 years or more than 10 years","MALE","30 Years",{"count":62,"type":21},"OBSERVATIONAL","The goal of this study is to test the effect of ionizing radiation on salivary Redox status among a group of ionizing radiation workers by measuring salivary biomarkers(malondialdehyde,8\\_hydroxy\\_deoxyguanosine and catalase) and measuring oral health condition by plaque index.\n\n90 male subjects will be enrolled in this study between 30\\_40 years old worked in Baghdad teaching hospital ,30 subjects exposed from computed tomography department ,30 subjects exposed from x\\_ray department and 30 subjects unexposed from laboratory department in the same hospitals.\n\nThe method of the study is taking unstimulated saliva sample from the subjects and oral health measure.",[158],"Salivary Redox Biomarkers and Oral Health","2025-06-05",{"date":161,"type":42},"2025-06-13",{"date":163,"type":21},"2025-06-25",{"date":165,"type":21},"2025-08-25",{"name":48,"class":49},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":58,"sex":17,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100589372","evaluation-of-the-salivary-free-amino-acids-levels-glycine--proline--lysine--and-alanine--with-caries-activity-100589372","NCT06953557","Evaluation of the Salivary-free Amino Acids Levels (Glycine , Proline , Lysine , and Alanine ) With Caries Activity","Evaluation of the Salivary-free Amino Acids Levels With Caries Activity","Inclusion Criteria:\n\n* Children aged (8,9,10) years with different caries\n* Absence of signs of gingivitis or periodontal disease.\n\nExclusion Criteria:\n\n* Children out the range of age\n* Children with any systemic discases.\n* Children with appliances in the mouth.\n* Children with appliances in the mouth.\n* Children with antibiotic treatment or any other drug over the last two weeks. B","8 Years","10 Years",{"count":177,"type":21},80,"This study will be aimed to investigated the correlation between levels of salivary amino acids (glycine , proline , lysine , alanine ) in the saliva of healthy children with and without active carious lesions and to estimate the predictive capacity of caries susceptibility",[180],"Dental Caries",[182],"Salivary -free amino acid measurment","2025-04-23",{"date":185,"type":42},"2025-05-01",{"date":187,"type":21},"2025-04-30",{"date":189,"type":21},"2025-06-30",{"name":48,"class":49},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":58,"sex":198,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":211,"locationsCount":4},"100589092","the-effect-of-body-mass-index-on-taste-perceptionsalivary-hormones-and-oral-health-status-100589092","NCT06949917","The Effect of Body Mass Index on Taste Perception,Salivary Hormones and Oral Health Status","Taste Perception,Oral Health Status and Selectied Salivary Hormones in Relation to Body Mass Index Among Agroup of Iraqi Adolescent Girls.","Inclusion Criteria:\n\n* female\n* 16-17 years old\n* subject with no systemic diseas.\n\nExclusion Criteria:\n\n* medically compressed patient\n* patient with systemic disease","FEMALE","16 Years","17 Years",{"count":62,"type":21},"the goal of the study is to test the effect of body mass index on adolesent Iraqi student girls by measuring salivary hormones (ghrelin,leptin,resistin)and measuring oral health by plague index score() and taste perception score () 90 female subject will be enrolled in this study between 16-17 years old,30 subjects with normal body weight ,30 subject overweight ,and 30 subject with obeiece group catogerize by body mass index according to age.\n\nthe methed of the study is by taking Saliva sample from the subject , taste perception score and oral health measure.",[204,205],"Oral Health","Tast Perference","2025-04-22",{"date":208,"type":42},"2025-04-29",{"date":187,"type":21},{"date":189,"type":21},{"name":48,"class":49},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":76},"100585324","phase-2-role-of-kefir-mouth-wash-in-oral-health-status-amelioration-100585324","NCT06900881","Role of Kefir Mouth Wash in Oral Health Status Amelioration","Role of Kefir Mouth Wash in Oral Health Status Amelioration: An in Vivo Study","Inclusion Criteria:\n\n* Age range 18-28 years.\n* Systemically healthy people without a history of chronic illness.\n* Those suffering with moderate gingivitis.\n* Not using any antibiotics over three months\n\nExclusion Criteria:\n\n* History of systemic diseases.\n* Pregnant, lactating females.\n* History of antibiotic therapy in the past 3 months.\n* History of oral prophylaxis within the last 6 months prior to the study as this can confound the results, making it difficult to determine the real effect of the mouthwash.\n* Subjects with mouth breathing habits.\n* Subjects with orthodontic and prosthodontic appliances.\n* Subjects with deleterious habits such as smoking, because it may affect oral health status, causing periodontal disease, altered oral microbiota, and impaired healing. This can confound the study results, making it difficult to observe the mouthwash effect .\n* Failure to follow the prescription regimen.\n* Failure to follow the research protocol.","28 Years",{"count":221,"type":21},60,[87,223],"PHASE3","The present research aims to evaluate the efficiency of kefir mouthwash in enhancing oral health status by employing an in vivo experimental approach. Specifically, the study will assess how kefir mouthwash influences key oral health indicators, including gingival inflammation, plaque development, oral hygiene status, and halitosis. The study will be conducted over a 28-day period, with follow-up assessments every 14 days. The study will include systemically healthy adults with moderate gingivitis. Clinical parameters such as the Gingival Index (GI), Plaque Index (PI), and Simplified Oral Hygiene Index (OHI-S) will be measured, along with inflammatory biomarkers, including Interleukin-1β (IL-1β) and Interleukin-10 (IL-10). Halitosis will be evaluated using a Hali meter device. All of these will be measured at base line and day 14 and day 28 end of the study. Chlorhexidine 0.12% will be used as a comparative control to evaluate the efficacy of kefir mouthwash in improving oral health. This research intends to provide scientific evidence supporting the use of kefir as a probiotic-based mouthwash, offering a natural alternative to chemical mouthwashes and potentially reducing the negative consequences commonly associated with their use.",[226,227,228],"Plaque Induced Gingivitis","Halitosis","Oral Disease",[230,231,227,232,233],"Kefir","Moderate gingivitis","Plaque","Oral Health Status",{"date":235,"type":42},"2025-04-24",{"date":237,"type":42},"2025-04-06",{"date":239,"type":21},"2025-10-10",{"name":48,"class":49},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":58,"sex":152,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100586638","evaluating-the-effects-of-psychological-stress-on-salivary-biomarkers-in-pediatric-patients-visiting-pediatric-and-general-dental-clinic-100586638","NCT06917976","Evaluating the Effects of Psychological Stress on Salivary Biomarkers in Pediatric Patients Visiting Pediatric and General Dental Clinic","Evaluating the Effects of Psychological Stress on Salivary Biomarkers in Pediatric Patients","Inclusion Criteria:\n\n* male\n* 4-6 years old\n* first dental visit\n* patients with no systemic disease\n\nExclusion Criteria:\n\n* medically compressed patient\n* patients with systemic disease","4 Years","6 Years",{"count":177,"type":21},"the goal of this study is to test the effect of psychological stress on pediatric patients visiting specialized and general dental clinic by measure salivary cortisol and salivary alpha amylase and by use children fear survey schedule -dental subscale .\n\n80 male subjects will be enrolled in this study between 4-6 years old with first dental visit ,40 subjects visiting specialized pediatric dental clinic to see the effect of specific environment and attitude of dentist on child stress ,and 40 subjects visiting general dental clinic with normal environment and general dentist .\n\nthe method of study is by taking two saliva sample from child , first when he will enter the clinic at reception and second after half hour when he will diagnosed without any type of treatment.",[253,254],"Salivary Cortisol","Salivary Alpha Amylase","2025-04-05",{"date":257,"type":42},"2025-04-09",{"date":259,"type":21},"2025-04-15",{"date":261,"type":21},"2025-06-15",{"name":48,"class":49},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":279,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":76},"100583917","phase-3-efficacy-of-resveratrol-containing-mouthwash-in-reducing-halitosis-related-porphyrymonas-gingivalis-100583917","NCT06882564","Efficacy of Resveratrol Containing Mouthwash in Reducing Halitosis Related Porphyrymonas Gingivalis.","Efficacy of Resveratrol Containing Mouthwash in Reducing Halitosis Related Porphyromonas Gingivalis: A Randomized, Triple-blind Clinical Trial","Inclusion Criteria:\n\n* Organoleptic tongue of scores \\> 2 using (0-5scale) (Rosenberg and McCulloch, 1992)\n* Male and female undergraduate dental students without chemical plaque control measures for at least one weak\n* Male and female students with halitosis due to gingivitis\n* The age of students ranges from 20 to 23 years.\n* No periodontal treatment for at least one month\n* No systemic disease\n* No tobacco smoking\n* The patients must have at least 20 teeth\n\nExclusion Criteria:\n\n* Smokers and alcoholics\n* Patient with periodontitis or pocket depth \\> 6mm\n* Patient with orthodontics appliance\n* Open carious lesions, pericoronitis, dry socket, and fistula.\n* Patients with systemic disease and condition\n* taking medication in the last two weeks\n* Take garlic, onion, or licorice in the last 24 hours\n* using oral hygiene products in the last 24 hours\n* pregnant women\n* sinusitis, tonsilitis, and upper respiratory tract infection",{"count":271,"type":21},54,[223],"The aim of the study:\n\nTo assess the efficacy of antioxidant (resveratrol) mouthwash in reducing the level of p. gingivitis and oral malodor over 7 day period among undergraduate dental student patients from Mustansiriyah University\u002FCollege of Dentistry and Wasit University \u002FCollege of Dentistry.\n\nObjectives:\n\n* To assess the efficacy of anti-oxidant and anti-inflammatory resveratrol mouthwash in reducing halitosis in undergraduate students with plaque-induced gingivitis patients.\n* To assess the efficacy of resveratrol mouthwash in reducing p. gingivalis in undergraduate students' patients with oral malodor.\n* To determine the relation between p.gingivalis and clinical periodontal parameters (plaque index, gingival index, bleeding on probing) among undergraduate students with plaque-induced gingivitis and halitosis.",[227,275,276,277,278],"Mouth Disease","Plaque Induced Gingival Disease","Bleeding Gum","Peridontal Disease",[280,281,282,283,284],"halitosis","plaque","gingivitis","resveratrol","chlorhexidine","2025-03-16",{"date":287,"type":42},"2025-03-18",{"date":289,"type":42},"2025-01-05",{"date":291,"type":21},"2025-11-01",{"name":48,"class":49},""]